The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD
Key facts
- Who runs it
- Shanghai Mental Health Center
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 30 Jul 2021
- Ended
- 29 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- deep brain stimulation
- Record updated
- 6 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- aged 18-65 years old
- a diagnosis of OCD based on The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)
- suffered from severe OCD symptoms over 5 years with substantial functional impairment
- the Y-BOCS total score ≥ 25
- met the criteria of treatment refractory. Treatment refractory is defined as failed 1) at least three adequate therapeutic trials of serotin reuptake inhibitors (SRIs), with clomipramine being one of the SRIs trials, 2) the use of at least two atypical antipsychotics as augmenting agents, 3) at least 12 sessions of therapist-guided cognitive-behavioral therapy while on a therapeutic dose of an SRIs. These patients have "failed" treatment by demonstrating <25% reduction of Y-BOCS scores or, despite >25% reduction in YBOCS score, by still experiencing significant impairment from their illness
Who cannot take part
- a history of current or past diagnosis of any psychosis according to DSM-5 except for OCD
- any clinical significant neurological disorder, traumatic brain injury, dementia, or medical illness
- any contradiction of neurosurgery
- any current or unstably remitted substance abuse or dependence
- women who are pregnant or preparing for pregnant
- severe suicide risk and tendency according to the investigators' judgements
- participate in any other clinical trials within three months (except for registered studies)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The present study aims to explore the efficacy and safety of DBS targeted the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC/NAcc-DBS) to refractory OCD, based on multicenter, randomized, double-blinded, sham-stimulation controlled design, that could help to obtain stronger evidence of the efficacy of multiple targets.
The 2 groups in the trial
- DBS true-stimulation groupExisting treatment, for comparison
The electrical stimulation will be 'turned-on' immediately after programming in true-stimulation group.
Treatment: deep brain stimulation
- DBS sham-stimulation groupSham treatment, for comparison
The electrical stimulation will be 'turned-off' after programming in sham-stimulation group. The stimulation will begin until after completing three months of Y-BOCS and CGI assessments
Treatment: deep brain stimulation
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Efficacy and Safety of Deep Brain Stimulation of Combined Anterior Limb of Internal Capsule and Nucleus Accumbens (ALIC/NAcc-DBS) for Treatment-refractory Obsessive-compulsive Disorder (OCD)
- Record updated
- 6 July 2026